CN102639131A - 舌下右美托咪定组合物及其使用方法 - Google Patents

舌下右美托咪定组合物及其使用方法 Download PDF

Info

Publication number
CN102639131A
CN102639131A CN2010800211820A CN201080021182A CN102639131A CN 102639131 A CN102639131 A CN 102639131A CN 2010800211820 A CN2010800211820 A CN 2010800211820A CN 201080021182 A CN201080021182 A CN 201080021182A CN 102639131 A CN102639131 A CN 102639131A
Authority
CN
China
Prior art keywords
dexmedetomidine
analgesic
composition
mucosa
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2010800211820A
Other languages
English (en)
Chinese (zh)
Inventor
杰拉尔丁·安妮·亨伍德
兰德尔·杰罗姆·马克
克里斯托弗·托马斯·萨尔
小约翰·约瑟夫·科伦格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Recro Pharma Inc
Original Assignee
Recro Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43085620&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN102639131(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Recro Pharma Inc filed Critical Recro Pharma Inc
Priority to CN201610753813.7A priority Critical patent/CN106511273A/zh
Publication of CN102639131A publication Critical patent/CN102639131A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2210/00—Anatomical parts of the body
    • A61M2210/06—Head
    • A61M2210/0625—Mouth

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN2010800211820A 2009-05-15 2010-05-17 舌下右美托咪定组合物及其使用方法 Pending CN102639131A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201610753813.7A CN106511273A (zh) 2009-05-15 2010-05-17 舌下右美托咪定组合物及其使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17873009P 2009-05-15 2009-05-15
US61/178,730 2009-05-15
PCT/US2010/035136 WO2010132882A2 (en) 2009-05-15 2010-05-17 Sublingual dexmedetomidine compositions and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201610753813.7A Division CN106511273A (zh) 2009-05-15 2010-05-17 舌下右美托咪定组合物及其使用方法

Publications (1)

Publication Number Publication Date
CN102639131A true CN102639131A (zh) 2012-08-15

Family

ID=43085620

Family Applications (2)

Application Number Title Priority Date Filing Date
CN2010800211820A Pending CN102639131A (zh) 2009-05-15 2010-05-17 舌下右美托咪定组合物及其使用方法
CN201610753813.7A Pending CN106511273A (zh) 2009-05-15 2010-05-17 舌下右美托咪定组合物及其使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201610753813.7A Pending CN106511273A (zh) 2009-05-15 2010-05-17 舌下右美托咪定组合物及其使用方法

Country Status (21)

Country Link
US (1) US20110021588A1 (https=)
EP (2) EP2429521B1 (https=)
JP (2) JP6172938B2 (https=)
KR (1) KR101859486B1 (https=)
CN (2) CN102639131A (https=)
AU (1) AU2010248776B2 (https=)
BR (1) BRPI1010567A2 (https=)
CA (1) CA2762107A1 (https=)
CL (1) CL2011002858A1 (https=)
CO (1) CO6460767A2 (https=)
CR (1) CR20110596A (https=)
DO (1) DOP2011000354A (https=)
EC (1) ECSP11011459A (https=)
HN (1) HN2011003011A (https=)
IL (1) IL216159A (https=)
MX (1) MX2011011950A (https=)
NZ (1) NZ596976A (https=)
PE (1) PE20120713A1 (https=)
RU (1) RU2572692C2 (https=)
SG (1) SG175979A1 (https=)
WO (1) WO2010132882A2 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112138250A (zh) * 2019-06-28 2020-12-29 四川普锐特药业有限公司 保持给药均一度的药物流体分配器及右美托咪定鼻喷器
CN113827590A (zh) * 2020-06-08 2021-12-24 四川普锐特药业有限公司 右美托咪定在助眠药物制备中的应用

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130096170A1 (en) 2011-10-14 2013-04-18 Hospira, Inc. Methods of treating pediatric patients using dexmedetomidine
WO2013090278A2 (en) * 2011-12-11 2013-06-20 Recro Pharma, Inc. Intranasal dexmedetomidine compositions and methods of use thereof
US8242158B1 (en) 2012-01-04 2012-08-14 Hospira, Inc. Dexmedetomidine premix formulation
JP2015517980A (ja) * 2012-02-27 2015-06-25 アイ・セラピーズ・エル・エル・シー 片頭痛の治療のための組成物および方法
CA2884926C (en) * 2012-10-15 2021-09-21 Orion Corporation A veterinary method of alleviating noise aversion
EP2792352A1 (en) * 2013-04-16 2014-10-22 Laboratorios Del. Dr. Esteve, S.A. Alpha-2 adrenoreceptor and sigma receptor ligand combinations
US20150273215A1 (en) * 2014-03-26 2015-10-01 Pacesetter, Inc. Systems and methods for assessment of pain and other parameters during trial neurostimulation
CA2924233C (en) 2013-10-07 2018-10-23 Teikoku Pharma Usa, Inc. Methods and compositions for treating attention deficit hyperactivity disorder, anxiety and insomnia using dexmedetomidine transdermal compositions
CA2924236C (en) 2013-10-07 2020-01-07 Teikoku Pharma Usa, Inc. Methods and compositions for transdermal delivery of a non-sedative amount of dexmedetomidine
KR101948779B1 (ko) * 2013-10-07 2019-05-21 테이코쿠 팔마 유에스에이, 인코포레이티드 덱스메데토미딘 경피 전달 장치 및 이의 사용 방법
RU2557882C1 (ru) * 2014-07-08 2015-07-27 Государственное бюджетное образовательное учреждение высшего профессионального образования "Астраханская государственная медицинская академия" Министерства здравоохранения Российской Федерации (ГБОУ ВПО АГМА Минздрава России) Способ проведения премедикации при плановом хирургическом лечении
MA41689A (fr) * 2014-10-15 2017-08-22 Bioxcel Corp Prévention ou traitement de troubles du sommeil au moyen d'une formulation de dexmédétomidine
BR112019006955A2 (pt) 2016-10-31 2019-07-02 Teikoku Pharma Usa Inc métodos de controle da dor usando dispositivos de distribuição transdérmica de dexmedetomidina
EP3554501B1 (en) * 2016-12-13 2021-06-09 Orion Corporation Dexmedetomidine or medetomidine for use in treating separation anxiety in companion animals
IL267689B2 (en) 2016-12-31 2025-05-01 Bioxcel Therapeutics Inc Use of sublingual dexmedetomidine for the treatment of agitation
BR112020026672A2 (pt) 2018-06-27 2021-03-30 Bioxcel Therapeutics, Inc. Formulações de filme contendo dexmedetomidina e métodos para produzi-las
US12472158B2 (en) 2019-02-27 2025-11-18 Vanderbilt University Methods of treating trigeminal nerve pain
BR112022000992A2 (pt) 2019-07-19 2022-06-14 Arx Llc Regimes de tratamento de dexmedetomidina não sedantes
US20220031664A1 (en) * 2020-07-28 2022-02-03 Melt Pharmaceuticals, Inc. Pharmaceutical compositions comprising antiemetics and alpha-2-adrenergic receptor agonists and methods of using the same for anesthesiological applications
JP2025531884A (ja) * 2022-09-11 2025-09-25 バイオエクセル セラピューティクス，インコーポレイテッド 社会環境における激越の処置方法
US11806334B1 (en) 2023-01-12 2023-11-07 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens
CN118542852B (zh) * 2024-07-30 2024-10-01 山东则正医药技术有限公司 包含经口给药的右美托咪定舌下膜组合物及其制备方法和应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050281752A1 (en) * 1997-10-01 2005-12-22 Dugger Harry A Iii Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2206880B (en) * 1987-07-16 1991-04-24 Farmos Oy Optical isomers of an imidazole derivative
US5217718A (en) * 1989-08-18 1993-06-08 Cygnus Therapeutic Systems Method and device for administering dexmedetomidine transdermally
US5124157A (en) * 1989-08-18 1992-06-23 Cygnus Therapeutic Systems Method and device for administering dexmedetomidine transdermally
FI894911A0 (fi) * 1989-10-17 1989-10-17 Farmos Oy En terapeutiskt vaerdefull foerening.
EP1875917A3 (en) * 1990-12-05 2012-11-28 The General Hospital Corporation Use of NO for the treatment or prevention of reversible pulmonary vasoconstriction
GB9111732D0 (en) * 1991-05-31 1991-07-24 Orion Yhtymae Oy The use of certain salts of medetomidine and its optically active enantiomers to regulate the rate of transdermal administration of the drugs
US5571840A (en) * 1993-06-22 1996-11-05 The Regents Of The University Of Michigan Method for treating central nervous system ischemia
US5713907A (en) * 1995-07-20 1998-02-03 Endotex Interventional Systems, Inc. Apparatus and method for dilating a lumen and for inserting an intraluminal graft
GB9520150D0 (en) 1995-10-03 1995-12-06 Orion Yhtymae Oy New imidazole derivatives
US20030077227A1 (en) * 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
US6716867B1 (en) 1998-04-01 2004-04-06 Orion Corporation Use of dexmedetomidine for ICU sedation
AR015744A1 (es) * 1998-04-01 2001-05-16 Orion Corp Uso de dexmedetomidina para sedacion en terapia intensiva
US7001609B1 (en) * 1998-10-02 2006-02-21 Regents Of The University Of Minnesota Mucosal originated drug delivery systems and animal applications
MXPA01003310A (es) * 1998-10-02 2003-05-15 3M Innovative Properties Co Sistema de suministro de farmaco originados en mucosa y aplicaciones animales.
GB9913677D0 (en) * 1999-06-11 1999-08-11 Imperial College Formulation
AUPR184500A0 (en) * 2000-12-01 2001-01-04 Drug Delivery Solutions Pty Ltd Dispensing device
WO2002089794A1 (en) * 2001-05-07 2002-11-14 Universite Catholique De Louvain Method for treating neuropathic pain and pharmaceutical preparation therefor
WO2002094238A1 (en) * 2001-05-24 2002-11-28 Alexza Molecular Delivery Corporation Delivery of anti-migraine compounds through an inhalation route
FR2834212B1 (fr) * 2001-12-27 2004-07-09 Besins Int Belgique Utilisation d'une poudre a liberation immediate dans des compositions pharmaceutiques et nutraceutiques
IL147921A0 (en) * 2002-01-31 2002-08-14 Abdulrazik Mohammad A method for treating central nervous system disorders by ocular dosing
US7439241B2 (en) * 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
WO2006105205A1 (en) * 2005-03-29 2006-10-05 University Of Kentucky Research Foundation Sublingual spray for the treatment of pain
ES2535233T3 (es) * 2006-01-25 2015-05-06 Insys Therapeutics, Inc. Pulverización de fentanilo sublingual
NZ570492A (en) * 2006-02-13 2011-08-26 Orient Pharma Samoa Co Ltd Combination of alpha-2 receptor agonist (clonidin) and an anti-muscarinic agent (oxybutynin) for the treatment of excess salivation or drooling
WO2008003093A2 (en) * 2006-06-29 2008-01-03 Questcor Pharmaceuticals, Inc. Pharmaceutical compositions and related methods of treatment
CN101057830A (zh) * 2007-05-10 2007-10-24 北京天川军威医药技术开发有限公司 盐酸纳洛酮舌下喷雾给药系统或组合物及其制备方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050281752A1 (en) * 1997-10-01 2005-12-22 Dugger Harry A Iii Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ANTTILA ET AL: "Bioavailability of dexmedetomidine after extravascular doses in healthy subjects", 《BR J CLIN PHARMACOL》, vol. 56, no. 6, 31 December 2003 (2003-12-31), pages 691 - 693, XP008155312, DOI: 10.1046/j.1365-2125.2003.01944.x *
HALL J.E ET AL: "Sedative,Amnestic, and Analgesic Properties of Small-Dose Dexmedetomidine Infusions", 《ANESTH ANALG》, vol. 90, no. 3, 31 March 2000 (2000-03-31), pages 699 - 705, XP008154643 *
KARAASLAN D.ET AL: "Comparison of buccal and intramuscular dexmedetomidine premedication for arthroscopic knee surgery", 《JOURNAL OF CLINICAL ANESTHESIA》, vol. 18, no. 8, 31 December 2006 (2006-12-31), pages 589 - 593, XP025079160, DOI: 10.1016/j.jclinane.2006.03.019 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112138250A (zh) * 2019-06-28 2020-12-29 四川普锐特药业有限公司 保持给药均一度的药物流体分配器及右美托咪定鼻喷器
CN112138250B (zh) * 2019-06-28 2023-04-14 四川普锐特药业有限公司 保持给药均一度的药物流体分配器及右美托咪定鼻喷器
CN113827590A (zh) * 2020-06-08 2021-12-24 四川普锐特药业有限公司 右美托咪定在助眠药物制备中的应用

Also Published As

Publication number Publication date
MX2011011950A (es) 2012-02-21
CA2762107A1 (en) 2010-11-18
DOP2011000354A (es) 2012-07-15
KR101859486B1 (ko) 2018-06-28
WO2010132882A3 (en) 2011-03-31
AU2010248776B2 (en) 2013-06-06
EP3305281A1 (en) 2018-04-11
US20110021588A1 (en) 2011-01-27
KR20120008058A (ko) 2012-01-25
WO2010132882A2 (en) 2010-11-18
EP2429521A4 (en) 2013-08-21
NZ596976A (en) 2014-05-30
EP2429521B1 (en) 2017-10-18
CL2011002858A1 (es) 2012-06-22
RU2572692C2 (ru) 2016-01-20
JP2012526854A (ja) 2012-11-01
WO2010132882A8 (en) 2011-12-29
CO6460767A2 (es) 2012-06-15
CN106511273A (zh) 2017-03-22
SG175979A1 (en) 2011-12-29
JP2016029055A (ja) 2016-03-03
IL216159A0 (en) 2012-01-31
HN2011003011A (es) 2014-12-01
PE20120713A1 (es) 2012-07-08
RU2011151059A (ru) 2013-06-20
CR20110596A (es) 2012-03-26
JP6172938B2 (ja) 2017-08-02
AU2010248776A1 (en) 2012-01-12
IL216159A (en) 2015-10-29
ECSP11011459A (es) 2012-01-31
EP2429521A2 (en) 2012-03-21
BRPI1010567A2 (pt) 2016-03-15

Similar Documents

Publication Publication Date Title
CN102639131A (zh) 舌下右美托咪定组合物及其使用方法
JP7621220B2 (ja) 疾患の処置のための鼻腔内エピネフリン製剤及び方法
JP6505177B2 (ja) 鼻腔内デクスメデトミジン組成物およびその使用方法
US9789071B2 (en) Intranasal formulation of epinephrine for the treatment of anaphylaxis
US20130072532A1 (en) Topical transdermal dexmedetomidine compositions and methods of use thereof
AU2004268602A2 (en) Intranasal opioid compositions
KR20010093255A (ko) 활성성분의 개선된 전달성을 갖는 조성물
KR102375232B1 (ko) 비강내 에피네프린 제제 및 질환의 치료 방법
HK1168302A (en) Sublingual dexmedetomidine compositions and methods of use thereof
HK1168302B (en) Sublingual dexmedetomidine compositions and methods of use thereof
HK40092206A (zh) 鼻内肾上腺素制剂及治疗疾病的方法
HK1203049B (en) Intranasal dexmedetomidine compositions and methods of use thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20120815